Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6246857 | 0.78 | ALDH1A1 (0.31) | ALDH1A1CFTRHSD17B10 | |
| SCHEMBL5327853 | 0.72 | — | — | |
| SCHEMBL13780268 | 0.70 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL4022918 | 0.69 | — | — | |
| SCHEMBL3348005 | 0.67 | POLB (0.32) | ALDH1A1HSD17B10 | |
| SCHEMBL6752183 | 0.67 | MEN1 (0.30) | — | |
| SCHEMBL28648656 | 0.66 | MEN1 (0.36) | ALDH1A1HSD17B10CA1CA2 | |
| SCHEMBL4822508 | 0.66 | MEN1 (0.30) | HSD17B10 | |
| SCHEMBL31543060 | 0.62 | — | — | |
| SCHEMBL31430625 | 0.62 | CA12 (0.32) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799913-B2 | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| CN-1620440-A | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses | CORTEX PHARMA INC (US) | 2005-05-25 | — | — | CN | disclosed |
| EP-1448537-A4 | CARBONYLBENZOXAZINE COMPOUNDS FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMA INC (US) | 2005-05-04 | — | — | EP | disclosed |
| US-20040259871-A1 | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC | 2004-12-23 | — | — | US | disclosed |
| EP-1448537-A2 | CARBONYLBENZOXAZINE COMPOUNDS FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003045315-A2 | CARBONYLBENZOXAZINE COMPOUNDS FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259871-A1 | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses | GAP43, GRIN2B, GRIN2A | ALDH1A1 2536/4885CFTR 4698/4885HSD17B10 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.